{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:41:32Z","timestamp":1792291292963,"version":"4.4.0"},"reference-count":219,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T00:00:00Z","timestamp":1524441600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA005010"],"award-info":[{"award-number":["DA005010"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"DOI":"10.3389\/fpsyt.2018.00119","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T09:24:30Z","timestamp":1524475470000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic"],"prefix":"10.3389","volume":"9","author":[{"given":"Amie L.","family":"Severino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Shadfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua K.","family":"Hakimian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Crane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganeev","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy M.","family":"Walwyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,4,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S1522-8649(03)50051-8","article-title":"Scophedal (SEE) was it a fad or a miracle drug?","volume":"21","author":"Defalque","year":"2003","journal-title":"Bull Anesth Hist"},{"key":"B2","author":"Rappaport","year":"2008"},{"key":"B3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3810\/pgm.2009.03.1988","article-title":"OxyContin abuse and overdose","volume":"121","author":"Aquina","year":"2009","journal-title":"Postgrad Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2105\/AJPH.2007.131714","article-title":"The promotion and marketing of oxycontin: commercial triumph, public health tragedy","volume":"99","author":"Van Zee","year":"2009","journal-title":"Am J Public Health"},{"key":"B5","first-page":"669","article-title":"Direct-to-consumer pharmaceutical advertising: therapeutic or toxic?","volume":"36","author":"Ventola","year":"2011","journal-title":"P T"},{"key":"B6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/MLR.0000000000000126","article-title":"Mind the gap: understanding the effects of pharmaceutical direct-to-consumer advertising","volume":"52","author":"Fain","year":"2014","journal-title":"Med Care"},{"key":"B7","volume-title":"Sackler Family [Online]","year":"2016"},{"key":"B8","unstructured":"OxyContin: Purdue Pharma\u2019s painful medicine EbanK Fortune2011"},{"key":"B9","unstructured":"Drug Overdose Deaths in the United States Continue to Increase in 2015 [Online]2016"},{"key":"B10","volume-title":"United States of America v. The Purdue Frederick Company, INC., et al","author":"Jones","year":"2007"},{"key":"B11","article-title":"Purdue Pharma to Stop Promoting OxyContin to U.S. Doctors","volume-title":"The Wall Street Journal","author":"Whalen","year":"2018"},{"key":"B12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/J354v19n02_04","article-title":"Non-medical use of oxycontin tablets in the United States","volume":"19","author":"Sees","year":"2005","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"B13","volume-title":"The DAWN Report: Highlights of the 2011 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits","year":"2013"},{"key":"B14","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.ejphar.2015.09.021","article-title":"Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice","volume":"765","author":"Zielinska","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in drug and opioid-involved overdose deaths \u2013 United States, 2010-2015","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1302\/0301-620X.99B7.BJJ-2016-1350.R1","article-title":"An epidemic of the use, misuse and overdose of opioids and deaths due to overdose, in the United States and Canada: is Europe next?","author":"Helmerhorst","year":"2017","journal-title":"Bone Joint J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/wps.20350","article-title":"Nonmedical use of prescription drugs in adolescents and young adults: not just a western phenomenon","volume":"16","author":"Martins","year":"2017","journal-title":"World Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12024-014-9624-x","article-title":"An update on oxycodone: lessons for death investigators in Australia","volume":"11","author":"Pilgrim","year":"2015","journal-title":"Forensic Sci Med Pathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.forsciint.2012.07.011","article-title":"Comparison of fatal poisonings by prescription opioids","volume":"222","author":"Hakkinen","year":"2012","journal-title":"Forensic Sci Int"},{"key":"B20","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/bcp.12133","article-title":"Prescription opioid abuse in the UK","volume":"76","author":"Giraudon","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.36076\/ppj.2008\/11\/S63","article-title":"Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids","volume":"11","author":"Manchikanti","year":"2008","journal-title":"Pain Physician"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1001\/jama.2008.802","article-title":"Patterns of abuse among unintentional pharmaceutical overdose fatalities","volume":"300","author":"Hall","year":"2008","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jsr.2014.09.001","article-title":"Variation among states in prescribing of opioid pain relievers and benzodiazepines \u2013 United States, 2012","volume":"51","author":"Paulozzi","year":"2014","journal-title":"J Safety Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6409a1","article-title":"Controlled substance prescribing patterns \u2013 prescription behavior surveillance system, eight states, 2013","volume":"64","author":"Paulozzi","year":"2015","journal-title":"MMWR Surveill Summ"},{"key":"B25","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/JOM.0000000000000435","article-title":"Comparison of mortality disparities in central appalachian coal- and non-coal-mining counties","volume":"57","author":"Woolley","year":"2015","journal-title":"J Occup Environ Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.drugalcdep.2007.09.018","article-title":"Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates","volume":"94","author":"Becker","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"B27","doi-asserted-by":"publisher","first-page":"15078","DOI":"10.1073\/pnas.1518393112","article-title":"Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century","volume":"112","author":"Case","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.emc.2015.11.002","article-title":"The opioid epidemic in the United States","volume":"34","author":"Wilkerson","year":"2016","journal-title":"Emerg Med Clin North Am"},{"key":"B29","volume-title":"Drug Overdose Deaths in the United States, 1999-2015","author":"Hedegaard","year":"2017"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1353\/eca.2017.0005","article-title":"Mortality and morbidity in the 21st century","author":"Case","year":"2017","journal-title":"Brookings Papers on Economic Activity"},{"key":"B31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1037\/ort0000120","article-title":"Toxic stress, behavioral health, and the next major era in public health","volume":"86","author":"Shern","year":"2016","journal-title":"Am J Orthopsychiatry"},{"key":"B32","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2105\/AJPH.2014.302219","article-title":"Psychological well-being during the great recession: changes in mental health care utilization in an occupational cohort","volume":"105","author":"Modrek","year":"2015","journal-title":"Am J Public Health"},{"key":"B33","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jhealeco.2017.07.009","article-title":"Macroeconomic conditions and opioid abuse","volume":"56","author":"Hollingsworth","year":"2017","journal-title":"J Health Econ"},{"key":"B34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.drugpo.2017.03.013","article-title":"How economic recessions and unemployment affect illegal drug use: a systematic realist literature review","volume":"44","author":"Nagelhout","year":"2017","journal-title":"Int J Drug Policy"},{"key":"B35","first-page":"S2","article-title":"Perspectives on the medical use of drugs of abuse","volume":"5","author":"Friedman","year":"1990","journal-title":"J Pain Symptom Manage"},{"key":"B36","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/01376517-199012000-00003","article-title":"Acute pain and substance abuse in surgical patients","volume":"22","author":"Tucker","year":"1990","journal-title":"J Neurosci Nurs"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/0140-6736(91)92968-8","article-title":"Undertreatment of cancer pain","volume":"337","author":"Tunca","year":"1991","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/archpsyc.1972.01750230096019","article-title":"Heroin use in Vietnam and the United States. A contrast and a critique","volume":"26","author":"Zinberg","year":"1972","journal-title":"Arch Gen Psychiatry"},{"key":"B39","doi-asserted-by":"crossref","first-page":"ES9","DOI":"10.36076\/ppj.2012\/15\/ES9","article-title":"Opioid epidemic in the United States","volume":"15","author":"Manchikanti","year":"2012","journal-title":"Pain Physician"},{"key":"B40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.brainres.2008.03.088","article-title":"Contributions of nucleus accumbens core and shell GluR1 containing AMPA receptors in AMPA- and cocaine-primed reinstatement of cocaine-seeking behavior","volume":"1215","author":"Ping","year":"2008","journal-title":"Brain Res"},{"key":"B41","first-page":"e41","article-title":"Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000-2010","volume":"6","author":"Kenan","year":"2012","journal-title":"Open Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.addbeh.2016.03.031","article-title":"Knowledge and beliefs about electronic cigarettes among quitline cessation staff","volume":"60","author":"Cummins","year":"2016","journal-title":"Addict Behav"},{"key":"B43","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1097\/MLR.0b013e3182a95d86","article-title":"Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000-2010","volume":"51","author":"Daubresse","year":"2013","journal-title":"Med Care"},{"key":"B44","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ajem.2014.01.015","article-title":"Prevalence and treatment of pain in EDs in the United States, 2000 to 2010","volume":"32","author":"Chang","year":"2014","journal-title":"Am J Emerg Med"},{"key":"B45","article-title":"Summary","volume-title":"Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research (2011)","year":"2011"},{"key":"B46","volume-title":"America\u2019s Addiction to Opioids: Heroin and Prescription Drug Abuse","author":"Volkow","year":"2014"},{"key":"B47","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJM198001103020221","article-title":"Addiction rare in patients treated with narcotics","volume":"302","author":"Porter","year":"1980","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0304-3959(82)90016-1","article-title":"Management of pain during debridement: a survey of U.S. burn units","volume":"13","author":"Perry","year":"1982","journal-title":"Pain"},{"key":"B49","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0304-3959(86)90091-6","article-title":"Chronic use of opioid analgesics in non-malignant pain: report of 38 cases","volume":"25","author":"Portenoy","year":"1986","journal-title":"Pain"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1056\/NEJMc1700150","article-title":"A 1980 letter on the risk of opioid addiction","volume":"376","author":"Leung","year":"2017","journal-title":"N Engl J Med"},{"key":"B51","volume-title":"Opioid Use Disorder: Update on Diagnosis and Treatment [Online]","author":"Brezing","year":"2015"},{"key":"B52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/00002508-199206000-00003","article-title":"Drug abuse, dependence, and addiction in chronic pain patients","volume":"8","author":"Fishbain","year":"1992","journal-title":"Clin J Pain"},{"key":"B53","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3109\/10826089509055820","article-title":"Prevalence of abuse and dependency in chronic pain patients","volume":"30","author":"Hoffmann","year":"1995","journal-title":"Int J Addict"},{"key":"B54","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/00002508-199706000-00009","article-title":"Prescription opiate abuse in chronic pain patients: clinical criteria, incidence, and predictors","volume":"13","author":"Chabal","year":"1997","journal-title":"Clin J Pain"},{"key":"B55","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0022-3999(97)00171-2","article-title":"Medication misuse, abuse and dependence in chronic pain patients","volume":"43","author":"Kouyanou","year":"1997","journal-title":"J Psychosom Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1046\/j.1525-1497.2002.10435.x","article-title":"Use of opioid medications for chronic noncancer pain syndromes in primary care","volume":"17","author":"Reid","year":"2002","journal-title":"J Gen Intern Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1213\/01.ANE.0000080159.83342.B5","article-title":"Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy","volume":"97","author":"Katz","year":"2003","journal-title":"Anesth Analg"},{"key":"B58","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/j.1526-4637.2006.00200.x","article-title":"Do users of regularly prescribed opioids have higher rates of substance use problems than nonusers?","volume":"8","author":"Edlund","year":"2007","journal-title":"Pain Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.ejpain.2006.08.004","article-title":"Addiction to opioids in chronic pain patients: a literature review","volume":"11","author":"Hojsted","year":"2007","journal-title":"Eur J Pain"},{"key":"B60","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/AJP.0b013e31802b4f95","article-title":"Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings","volume":"23","author":"Michna","year":"2007","journal-title":"Clin J Pain"},{"key":"B61","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1526-4637.2007.00370.x","article-title":"What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse\/addiction and\/or aberrant drug-related behaviors? A structured evidence-based review","volume":"9","author":"Fishbain","year":"2008","journal-title":"Pain Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/01.j.pain.0000460357.01998.f1","article-title":"Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis","volume":"156","author":"Vowles","year":"2015","journal-title":"Pain"},{"key":"B63","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/pm\/pnw134","article-title":"Problematic use of prescription opioids and medicinal cannabis among patients suffering from chronic pain","volume":"18","author":"Feingold","year":"2017","journal-title":"Pain Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.2174\/138161209788168100","article-title":"Opiates as antidepressants","volume":"15","author":"Berrocoso","year":"2009","journal-title":"Curr Pharm Des"},{"key":"B65","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/ACO.0000000000000116","article-title":"The anxiodepressive comorbidity in chronic pain","volume":"27","author":"Yalcin","year":"2014","journal-title":"Curr Opin Anaesthesiol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1001\/jamapsychiatry.2014.3043","article-title":"Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from oxycontin","volume":"72","author":"Cicero","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"B67","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.bbr.2014.04.042","article-title":"Pain and depression comorbidity: a preclinical perspective","volume":"276","author":"Li","year":"2015","journal-title":"Behav Brain Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jpain.2015.12.012","article-title":"Increased risk of depression recurrence after initiation of prescription opioids in noncancer pain patients","volume":"17","author":"Scherrer","year":"2016","journal-title":"J Pain"},{"key":"B69","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/ALN.0000000000000768","article-title":"Psychiatric comorbidity is associated prospectively with diminished opioid analgesia and increased opioid misuse in patients with chronic low back pain","volume":"123","author":"Wasan","year":"2015","journal-title":"Anesthesiology"},{"key":"B70","first-page":"295","article-title":"Evaluation of how depression and anxiety mediate the relationship between pain catastrophizing and prescription opioid misuse in a chronic pain population","volume":"17","author":"Arteta","year":"2016","journal-title":"Pain Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1093\/pm\/pnw010","article-title":"Changes in pain sensitivity and pain modulation during oral opioid treatment: the impact of negative affect","volume":"17","author":"Edwards","year":"2016","journal-title":"Pain Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/clpt.1985.179","article-title":"Kinetics of cocaine distribution, elimination, and chronotropic effects","volume":"38","author":"Chow","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1586\/ern.12.123","article-title":"Medical management of acute pain in patients with chronic pain","volume":"12","author":"De Pinto","year":"2012","journal-title":"Expert Rev Neurother"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1176\/appi.ajp.2016.15091179","article-title":"Pain as a predictor of opioid use disorder in a nationally representative sample","volume":"173","author":"Blanco","year":"2016","journal-title":"Am J Psychiatry"},{"key":"B75","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1037\/h0036128","article-title":"An opponent-process theory of motivation. I. Temporal dynamics of affect","volume":"81","author":"Solomon","year":"1974","journal-title":"Psychol Rev"},{"key":"B76","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/bs.pbr.2015.09.001","article-title":"Neuroscience of opiates for addiction medicine: from stress-responsive systems to behavior","volume":"223","author":"Zhou","year":"2016","journal-title":"Prog Brain Res"},{"key":"B77","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.pnpbp.2003.09.029","article-title":"Aggressive responding in abstinent heroin addicts: neuroendocrine and personality correlates","volume":"28","author":"Gerra","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B78","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.biopsych.2007.05.001","article-title":"Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence","volume":"63","author":"Kakko","year":"2008","journal-title":"Biol Psychiatry"},{"key":"B79","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0165-0173(93)90013-P","article-title":"The neural basis of drug craving: an incentive-sensitization theory of addiction","volume":"18","author":"Robinson","year":"1993","journal-title":"Brain Res Brain Res Rev"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1176\/appi.ajp.162.8.1403","article-title":"The neural basis of addiction: a pathology of motivation and choice","volume":"162","author":"Kalivas","year":"2005","journal-title":"Am J Psychiatry"},{"key":"B81","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: a neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"B82","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1056\/NEJMra1511480","article-title":"Neurobiologic advances from the brain disease model of addiction","volume":"374","author":"Volkow","year":"2016","journal-title":"N Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0893-133X(00)00195-0","article-title":"Drug addiction, dysregulation of reward, and allostasis","volume":"24","author":"Koob","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"B84","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00213-016-4494-4","article-title":"Deficits in autonomic indices of emotion regulation and reward processing associated with prescription opioid use and misuse","volume":"234","author":"Garland","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"B85","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.brainresbull.2015.12.004","article-title":"Evidence of anhedonia and differential reward processing in prefrontal cortex among post-withdrawal patients with prescription opiate dependence","volume":"123","author":"Huhn","year":"2016","journal-title":"Brain Res Bull"},{"key":"B86","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/FBP.0000000000000207","article-title":"Pharmacological modulation of neuropathic pain-related depression of behavior: effects of morphine, ketoprofen, bupropion and [INCREMENT]9-tetrahydrocannabinol on formalin-induced depression of intracranial self-stimulation in rats","volume":"27","author":"Leitl","year":"2016","journal-title":"Behav Pharmacol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2017.07.029","article-title":"The risk for problematic opioid use in chronic pain: what can we learn from studies of pain and reward?","author":"Finan","year":"2017","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/ejp.687","article-title":"Reward responsiveness in patients with chronic pain","volume":"19","author":"Elvemo","year":"2015","journal-title":"Eur J Pain"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1089\/neu.2011.2100","article-title":"Analgesia or addiction? Implications for morphine use after spinal cord injury","volume":"29","author":"Woller","year":"2012","journal-title":"J Neurotrauma"},{"key":"B90","doi-asserted-by":"publisher","first-page":"12217","DOI":"10.1523\/JNEUROSCI.1053-15.2015","article-title":"Inflammatory pain promotes increased opioid self-administration: role of dysregulated ventral tegmental area mu opioid receptors","volume":"35","author":"Hipolito","year":"2015","journal-title":"J Neurosci"},{"key":"B91","doi-asserted-by":"publisher","first-page":"10290","DOI":"10.1523\/JNEUROSCI.0715-15.2015","article-title":"Persistent adaptations in afferents to ventral tegmental dopamine neurons after opiate withdrawal","volume":"35","author":"Kaufling","year":"2015","journal-title":"J Neurosci"},{"key":"B92","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/adb.12120","article-title":"Chronic CRF1 receptor blockade reduces heroin intake escalation and dependence-induced hyperalgesia","volume":"20","author":"Park","year":"2015","journal-title":"Addict Biol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/npp.2014.188","article-title":"Compulsive-like responding for opioid analgesics in rats with extended access","volume":"40","author":"Wade","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e79239","DOI":"10.1371\/journal.pone.0079239","article-title":"Effect of chronic pain on fentanyl self-administration in mice","volume":"8","author":"Wade","year":"2013","journal-title":"PLoS One"},{"key":"B95","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40262-012-0016-7","article-title":"Pharmacokinetics of non-intravenous formulations of fentanyl","volume":"52","author":"Lotsch","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"B96","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1523\/JNEUROSCI.3453-14.2015","article-title":"Persistent pain maintains morphine-seeking behavior after morphine withdrawal through reduced MeCP2 repression of GluA1 in rat central amygdala","volume":"35","author":"Hou","year":"2015","journal-title":"J Neurosci"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/add.13782","article-title":"Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction","volume":"112","author":"Worley","year":"2017","journal-title":"Addiction"},{"key":"B98","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","article-title":"Update on barriers to pharmacotherapy for opioid use disorders","volume":"19","author":"Sharma","year":"2017","journal-title":"Curr Psychiatry Rep"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"B100","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1037\/pha0000039","article-title":"Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain","volume":"23","author":"Worley","year":"2015","journal-title":"Exp Clin Psychopharmacol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.drugalcdep.2016.04.023","article-title":"Longitudinal association between pain severity and subsequent opioid use in prescription opioid dependent patients with chronic pain","volume":"163","author":"Griffin","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"B102","doi-asserted-by":"publisher","first-page":"7525","DOI":"10.1021\/acs.jmedchem.6b00516","article-title":"Peripherally selective cannabinoid 1 receptor (cb1r) agonists for the treatment of neuropathic pain","volume":"59","author":"Seltzman","year":"2016","journal-title":"J Med Chem"},{"key":"B103","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11916-015-0517-9","article-title":"Psychological interventions for the management of chronic pain: a review of current evidence","volume":"19","author":"Kaiser","year":"2015","journal-title":"Curr Pain Headache Rep"},{"key":"B104","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/00003495-197917020-00001","article-title":"Buprenorphine: a review of its pharmacological properties and therapeutic efficacy","volume":"17","author":"Heel","year":"1979","journal-title":"Drugs"},{"key":"B105","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2174\/1570159043359477","article-title":"Buprenorphine: a unique drug with complex pharmacology","volume":"2","author":"Lutfy","year":"2004","journal-title":"Curr Neuropharmacol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1097\/ALN.0b013e318238fea0","article-title":"Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active","volume":"115","author":"Brown","year":"2011","journal-title":"Anesthesiology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ejpb.2013.01.018","article-title":"The transdermal delivery of fentanyl","volume":"84","author":"Lane","year":"2013","journal-title":"Eur J Pharm Biopharm"},{"key":"B108","doi-asserted-by":"crossref","first-page":"SE217","DOI":"10.36076\/ppj.2013\/16\/SE217","article-title":"An update of evaluation of intravenous sedation on diagnostic spinal injection procedures","volume":"16","author":"Smith","year":"2013","journal-title":"Pain Physician"},{"key":"B109","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0026-895X(25)09932-8","article-title":"Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors","volume":"45","author":"Raynor","year":"1994","journal-title":"Mol Pharmacol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/bcp.12051","article-title":"Pharmacological maintenance treatments of opiate addiction","volume":"77","author":"Bell","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1001\/jamapsychiatry.2016.0109","article-title":"Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial","volume":"73","author":"Oviedo-Joekes","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"B112","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/521281a","article-title":"Drugs: regulate \u2018home-brew\u2019 opiates","volume":"521","author":"Oye","year":"2015","journal-title":"Nature"},{"key":"B113","volume-title":"Opioids in Palliative Care: Safe and Effective Prescribing of Strong Opioids for Pain in Palliative Care of Adults","year":"2012"},{"key":"B114","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/JPR.S58862","article-title":"Management of breakthrough pain in children with cancer","volume":"7","author":"Friedrichsdorf","year":"2014","journal-title":"J Pain Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1465-3362.2010.00266.x","article-title":"Heroin maintenance treatment: from idea to research to practice","volume":"30","author":"Uchtenhagen","year":"2011","journal-title":"Drug Alcohol Rev"},{"key":"B116","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/bph.12305","article-title":"Levels of heroin and its metabolites in blood and brain extracellular fluid after i.v. heroin administration to freely moving rats","volume":"170","author":"Gottas","year":"2013","journal-title":"Br J Pharmacol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s40263-016-0357-0","article-title":"The clinical applications of extended-release abuse-deterrent opioids","volume":"30","author":"Vadivelu","year":"2016","journal-title":"CNS Drugs"},{"key":"B118","doi-asserted-by":"crossref","first-page":"E343","DOI":"10.36076\/ppj.2011\/14\/E343","article-title":"Pharmacology of opioids in the treatment of chronic pain syndromes","volume":"14","author":"Vallejo","year":"2011","journal-title":"Pain Physician"},{"key":"B119","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/pm\/pnv004","article-title":"Intranasal abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydrocodone (HYD) in recreational opioid users","volume":"17","author":"Harris","year":"2016","journal-title":"Pain Med"},{"key":"B120","unstructured":"Dilaudid2007"},{"key":"B121","volume-title":"Toxinet: Toxicology Data Network [Online]","year":"2016"},{"key":"B122","first-page":"CD011108","article-title":"Hydromorphone for cancer pain","volume":"10","author":"Bao","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B123","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s005200000183","article-title":"Hydromorphone: pharmacology and clinical applications in cancer patients","volume":"9","author":"Sarhill","year":"2001","journal-title":"Support Care Cancer"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1021\/jm0400597","article-title":"Identification of opioid ligands possessing mixed micro agonist\/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]","volume":"47","author":"Ananthan","year":"2004","journal-title":"J Med Chem"},{"key":"B125","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.36076\/ppj.2008\/11\/S133","article-title":"Opioid pharmacology","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Physician"},{"key":"B126","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-3565(25)25002-9","article-title":"Beneficial effects of calcium channel blockers and calmodulin binding drugs on in vitro renal cell anoxia","volume":"238","author":"Schwertschlag","year":"1986","journal-title":"J Pharmacol Exp Ther"},{"key":"B127","first-page":"435","article-title":"Pharmacology of methadone and its isomers","volume":"71","author":"Inturrisi","year":"2005","journal-title":"Minerva Anestesiol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2049463712438493","article-title":"Basic opioid pharmacology: an update","volume":"6","author":"Pathan","year":"2012","journal-title":"Br J Pain"},{"key":"B129","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/00000441-197312000-00006","article-title":"Serratia marcescens: use of detailed characterization of strains to evaluate an increase of isolates in an intensive care unit","volume":"266","author":"Cardos","year":"1973","journal-title":"Am J Med Sci"},{"key":"B130","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-0585-7","volume-title":"Opioid Analgesics [Online]","author":"Casy","year":"1986"},{"key":"B131","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1300\/J251v09n01_03","article-title":"The opioids: abuse liability and treatments for dependence","volume":"9","author":"Ternes","year":"1990","journal-title":"Adv Alcohol Subst Abuse"},{"key":"B132","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/pgmj.2004.022988","article-title":"Methadone: applied pharmacology and use as adjunctive treatment in chronic pain","volume":"80","author":"Brown","year":"2004","journal-title":"Postgrad Med J"},{"key":"B133","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1105\/tpc.113.115113","article-title":"Morphine biosynthesis in opium poppy involves two cell types: sieve elements and laticifers","volume":"25","author":"Onoyovwe","year":"2013","journal-title":"Plant Cell"},{"key":"B134","doi-asserted-by":"publisher","first-page":"540154","DOI":"10.1155\/2015\/540154","article-title":"Morphine for the treatment of pain in sickle cell disease","volume":"2015","author":"Gupta","year":"2015","journal-title":"ScientificWorldJournal"},{"key":"B135","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1021\/cn9000236","article-title":"Standard opioid agonists activate heteromeric opioid receptors: evidence for morphine and [d-Ala(2)-MePhe(4)-Glyol(5)]enkephalin as selective mu-delta agonists","volume":"1","author":"Yekkirala","year":"2010","journal-title":"ACS Chem Neurosci"},{"key":"B136","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s13181-012-0263-x","article-title":"Likeability and abuse liability of commonly prescribed opioids","volume":"8","author":"Wightman","year":"2012","journal-title":"J Med Toxicol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12094-007-0057-9","article-title":"Oxycodone: a pharmacological and clinical review","volume":"9","author":"Ordonez Gallego","year":"2007","journal-title":"Clin Transl Oncol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"6244","DOI":"10.1021\/ol503175n","article-title":"Synthesis of (-)-oxycodone","volume":"16","author":"Kimishima","year":"2014","journal-title":"Org Lett"},{"key":"B139","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/J354v16n04_02","article-title":"Clinical pharmacokinetics of morphine","volume":"16","author":"Lugo","year":"2002","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"B140","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1124\/dmd.108.022087","article-title":"Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone","volume":"36","author":"Okura","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"B141","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00520-005-0917-1","article-title":"Oxymorphone: a review","volume":"14","author":"Prommer","year":"2006","journal-title":"Support Care Cancer"},{"key":"B142","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.tips.2013.02.001","article-title":"Does the pharmacology of oxycodone justify its increasing use as an analgesic?","volume":"34","author":"Olkkola","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"B143","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0952-8180(96)00179-1","article-title":"The pharmacokinetics of remifentanil","volume":"8","author":"Michelsen","year":"1996","journal-title":"J Clin Anesth"},{"key":"B144","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/0471780103.ch12","article-title":"Discovery and development of the ultrashort-acting analgesic remifentanil","volume-title":"Drug Discovery and Development","author":"Feldman","year":"2006"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1097\/00000539-199911000-00038","article-title":"The use of a remifentanil infusion for hemodynamic control during intracranial surgery","volume":"89","author":"Gesztesi","year":"1999","journal-title":"Anesth Analg"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1213\/01.ANE.0000134684.25322.26","article-title":"Intraoperative wake-up test and postoperative emergence in patients undergoing spinal surgery: a comparison of intravenous and inhaled anesthetic techniques using short-acting anesthetics","volume":"99","author":"Grottke","year":"2004","journal-title":"Anesth Analg"},{"key":"B147","first-page":"I33","article-title":"Comparison of remifentanil or fentanyl administration during isoflurane anesthesia for coronary artery bypass surgery","volume":"12","author":"Knapik","year":"2006","journal-title":"Med Sci Monit"},{"key":"B148","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/bja\/aem164","article-title":"Influence of intraoperative opioid on postoperative pain and pulmonary function after laparoscopic gastric banding: remifentanil TCI vs sufentanil TCI in morbid obesity","volume":"99","author":"De Baerdemaeker","year":"2007","journal-title":"Br J Anaesth"},{"key":"B149","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2165\/00003495-199700532-00006","article-title":"[Pharmacology of tramadol]","volume":"53","author":"Dayer","year":"1997","journal-title":"Drugs"},{"key":"B150","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200443130-00004","article-title":"Clinical pharmacology of tramadol","volume":"43","author":"Grond","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"B151","first-page":"877","article-title":"Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids","volume":"38","author":"Hennies","year":"1988","journal-title":"Arzneimittelforschung"},{"key":"B152","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1734-1140(09)70159-8","article-title":"Tramadol as an analgesic for mild to moderate cancer pain","volume":"61","author":"Leppert","year":"2009","journal-title":"Pharmacol Rep"},{"key":"B153","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/pr.112.005942","article-title":"Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol Rev"},{"key":"B154","doi-asserted-by":"publisher","first-page":"9988","DOI":"10.1073\/pnas.0804246105","article-title":"Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors","volume":"105","author":"Shukla","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B155","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/bs.apha.2017.03.005","article-title":"Functional selectivity at cannabinoid receptors","volume":"80","author":"Priestley","year":"2017","journal-title":"Adv Pharmacol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.coph.2016.11.007","article-title":"Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics","volume":"32","author":"Siuda","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.pain.2014.06.011","article-title":"Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers","volume":"155","author":"Soergel","year":"2014","journal-title":"Pain"},{"key":"B158","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature19112","article-title":"Structure-based discovery of opioid analgesics with reduced side effects","volume":"537","author":"Manglik","year":"2016","journal-title":"Nature"},{"key":"B159","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1124\/jpet.117.241117","article-title":"TRV0109101, a G protein-biased agonist of the micro-opioid receptor, does not promote opioid-induced mechanical allodynia following chronic administration","volume":"362","author":"Koblish","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"B160","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1124\/jpet.112.201616","article-title":"A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine","volume":"344","author":"Dewire","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"B161","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1177\/0269881116689257","article-title":"Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents","volume":"31","author":"Altarifi","year":"2017","journal-title":"J Psychopharmacol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neuropharm.2010.08.003","article-title":"The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics","volume":"60","author":"Raehal","year":"2011","journal-title":"Neuropharmacology"},{"key":"B163","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/bph.12600","article-title":"Novel GPCR paradigms at the mu-opioid receptor","volume":"172","author":"Thompson","year":"2015","journal-title":"Br J Pharmacol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1152\/physrev.00005.2009","article-title":"Reward processing by the opioid system in the brain","volume":"89","author":"Le Merrer","year":"2009","journal-title":"Physiol Rev"},{"key":"B165","doi-asserted-by":"publisher","first-page":"R1287","DOI":"10.1152\/ajpregu.00199.2003","article-title":"Mu-opioid receptor agonist effects on medullary respiratory neurons in the cat: evidence for involvement in certain types of ventilatory disturbances","volume":"285","author":"Lalley","year":"2003","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/brain\/awq327","article-title":"Neuroanatomical characteristics of the human pre-Botzinger complex and its involvement in neurodegenerative brainstem diseases","volume":"134","author":"Schwarzacher","year":"2011","journal-title":"Brain"},{"key":"B167","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/j.1360-0443.1991.tb01754.x","article-title":"Pharmacokinetic considerations in abuse liability evaluation","volume":"86","author":"Farre","year":"1991","journal-title":"Br J Addict"},{"key":"B168","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5055\/jom.2009.0022","article-title":"Relationship between rate of infusion and reinforcing strength of oxycodone in humans","volume":"5","author":"Comer","year":"2009","journal-title":"J Opioid Manag"},{"key":"B169","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2165\/00003088-197601030-00004","article-title":"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone","volume":"1","author":"Berkowitz","year":"1976","journal-title":"Clin Pharmacokinet"},{"key":"B170","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1139\/y86-001","article-title":"The therapeutic use of heroin: a review of the pharmacological literature","volume":"64","author":"Sawynok","year":"1986","journal-title":"Can J Physiol Pharmacol"},{"key":"B171","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.drugpo.2017.06.004","article-title":"Heroin uncertainties: exploring users\u2019 perceptions of fentanyl-adulterated and -substituted \u2018heroin\u2019","volume":"46","author":"Ciccarone","year":"2017","journal-title":"Int J Drug Policy"},{"key":"B172","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0027-9684(15)30175-9","article-title":"Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options","volume":"104","author":"Bonhomme","year":"2012","journal-title":"J Natl Med Assoc"},{"key":"B173","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/adb.12163","article-title":"Abuse potential of intranasal buprenorphine versus buprenorphine\/naloxone in buprenorphine-maintained heroin users","volume":"20","author":"Jones","year":"2015","journal-title":"Addict Biol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1042\/cs0810655","article-title":"Intrathoracic airstream temperatures during acute expansions of thoracic blood volume","volume":"81","author":"Gilbert","year":"1991","journal-title":"Clin Sci (Lond)"},{"key":"B175","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","article-title":"Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence","volume":"44","author":"Elkader","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"B176","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/jat\/20.6.369","article-title":"Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine","volume":"20","author":"Kuhlman","year":"1996","journal-title":"J Anal Toxicol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1124\/jpet.112.193433","article-title":"P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception","volume":"343","author":"Brown","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"B178","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.2146\/ajhp140157","article-title":"The opioid abuse and misuse epidemic: implications for pharmacists in hospitals and health systems","volume":"71","author":"Cobaugh","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"B179","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMsa1406143","article-title":"Trends in opioid analgesic abuse and mortality in the United States","volume":"372","author":"Dart","year":"2015","journal-title":"N Engl J Med"},{"key":"B180","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugalcdep.2016.11.033","article-title":"A review: fentanyl and non-pharmaceutical fentanyls","volume":"171","author":"Suzuki","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"B181","doi-asserted-by":"publisher","first-page":"422","DOI":"10.2165\/00003088-198308050-00004","article-title":"Clinical pharmacokinetics of fentanyl and its newer derivatives","volume":"8","author":"Mather","year":"1983","journal-title":"Clin Pharmacokinet"},{"key":"B182","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","article-title":"Opioid metabolism","volume":"84","author":"Smith","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"B183","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40265-017-0727-z","article-title":"Fentanyl formulations in the management of pain: an update","volume":"77","author":"Schug","year":"2017","journal-title":"Drugs"},{"key":"B184","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.drugalcdep.2013.01.007","article-title":"Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers \u2013 United States, 2002-2004 and 2008-2010","volume":"132","author":"Jones","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"B185","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/clpt.1993.127","article-title":"The pharmacokinetics of morphine and morphine glucuronides in kidney failure","volume":"54","author":"Osborne","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"B186","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1126\/science.178.4064.984","article-title":"Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection","volume":"178","author":"Oldendorf","year":"1972","journal-title":"Science"},{"key":"B187","volume-title":"Kelley and Firestein\u2019s Textbook of Rheumatology E-Book","author":"Firestein","year":"2017"},{"key":"B188","volume-title":"Pharmacology for Women\u2019s Health","author":"Brucker","year":"2017"},{"key":"B189","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/j.1552-4604.1981.tb05693.x","article-title":"Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects","volume":"21","author":"Vallner","year":"1981","journal-title":"J Clin Pharmacol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/jat\/bku051","article-title":"Urinary hydrocodone and metabolite distributions in pain patients abuse potential of intranasal buprenorphine versus buprenorphine\/naloxone in buprenorphine-maintained heroin users","volume":"38","author":"Barakat","year":"2014","journal-title":"J Anal Toxicol"},{"key":"B191","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/jcph.501","article-title":"Single-dose evaluation of safety, tolerability and pharmacokinetics of newly formulated hydromorphone immediate-release and hydrophilic matrix extended-release tablets in healthy Japanese subjects without co-administration of an opioid antagonist","volume":"55","author":"Toyama","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"B192","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00002508-200207001-00002","article-title":"Clinical pharmacology of opioids for pain","volume":"18","author":"Inturrisi","year":"2002","journal-title":"Clin J Pain"},{"key":"B193","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0024-3205(01)01133-X","article-title":"Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide","volume":"69","author":"Wright","year":"2001","journal-title":"Life Sci"},{"key":"B194","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1213\/01.ANE.0000066311.40978.4F","article-title":"Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers","volume":"97","author":"Coda","year":"2003","journal-title":"Anesth Analg"},{"key":"B195","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.phrs.2004.05.002","article-title":"Methadone \u2013 metabolism, pharmacokinetics and interactions","volume":"50","author":"Ferrari","year":"2004","journal-title":"Pharmacol Res"},{"key":"B196","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/jat\/27.6.332","article-title":"Methadone and metabolite urine concentrations in patients maintained on methadone","volume":"27","author":"Preston","year":"2003","journal-title":"J Anal Toxicol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/med.20035","article-title":"Morphine-6-glucuronide: actions and mechanisms","volume":"25","author":"Kilpatrick","year":"2005","journal-title":"Med Res Rev"},{"key":"B198","first-page":"344","article-title":"Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations","volume":"24","author":"Hasselstrom","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"B199","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1399-6576.1997.tb04684.x","article-title":"Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone","volume":"41","author":"Takala","year":"1997","journal-title":"Acta Anaesthesiol Scand"},{"key":"B200","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.clpt.2006.01.009","article-title":"Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites","volume":"79","author":"Lalovic","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"B201","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1213\/ane.0b013e3181605a15","article-title":"Pharmacological characterization of noroxymorphone as a new opioid for spinal analgesia","volume":"106","author":"Lemberg","year":"2008","journal-title":"Anesth Analg"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1124\/dmd.106.009746","article-title":"In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics\/pharmacodynamics","volume":"34","author":"Bostrom","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"B203","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/00004714-200012000-00002","article-title":"Comparative abuse liability of intravenously administered remifentanil and fentanyl","volume":"20","author":"Baylon","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"B204","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1213\/ANE.0b013e3181c5f069","article-title":"Intranasal self-administration of remifentanil as the foray into opioid abuse by an anesthesia resident","volume":"110","author":"Levine","year":"2010","journal-title":"Anesth Analg"},{"key":"B205","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0022-3565(24)36558-9","article-title":"Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs","volume":"281","author":"Hoke","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"B206","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1399-6576.1997.tb04625.x","article-title":"Morphine metabolites","volume":"41","author":"Christrup","year":"1997","journal-title":"Acta Anaesthesiol Scand"},{"key":"B207","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1002\/jps.24129","article-title":"Transport characteristics of tramadol in the blood-brain barrier","volume":"103","author":"Kitamura","year":"2014","journal-title":"J Pharm Sci"},{"key":"B208","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1124\/jpet.117.243030","article-title":"NKTR-181: a novel mu-opioid analgesic with inherently low abuse potential","volume":"363","author":"Miyazaki","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"B209","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/pm\/pnw344","article-title":"Human abuse potential of the new opioid analgesic molecule NKTR-181 compared with oxycodone","volume":"19","author":"Webster","year":"2018","journal-title":"Pain Med"},{"key":"B210","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1016\/0024-3205(87)90065-8","article-title":"Bivalent opioid peptide analogues with reduced distances between pharmacophores","volume":"40","author":"Lipkowski","year":"1987","journal-title":"Life Sci"},{"key":"B211","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/jpet.109.157446","article-title":"Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor\/mu-opioid receptor ligands: implications for therapeutic applications","volume":"331","author":"Toll","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"B212","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1016\/j.bmcl.2013.03.101","article-title":"Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I","volume":"23","author":"Zaveri","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"B213","doi-asserted-by":"publisher","first-page":"e0156897","DOI":"10.1371\/journal.pone.0156897","article-title":"Characterisation of the novel mixed Mu-NOP peptide ligand dermorphin-N\/OFQ (DeNo)","volume":"11","author":"Bird","year":"2016","journal-title":"PLoS One"},{"key":"B214","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0196-9781(00)00252-7","article-title":"Agonistic effects of the opioid buprenorphine on the nociceptin\/OFQ receptor","volume":"21","author":"Bloms-Funke","year":"2000","journal-title":"Peptides"},{"key":"B215","doi-asserted-by":"crossref","first-page":"10331","DOI":"10.1523\/JNEUROSCI.23-32-10331.2003","article-title":"Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors","volume":"23","author":"Lutfy","year":"2003","journal-title":"J Neurosci"},{"key":"B216","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/jhet.2696","article-title":"Synthesis and investigation of mixed mu-opioid and delta-opioid agonists as possible bivalent ligands for treatment of pain","volume":"54","author":"Vardanyan","year":"2017","journal-title":"J Heterocycl Chem"},{"key":"B217","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1097\/j.pain.0000000000001050","article-title":"Bivalent ligand that activates mu opioid receptor and antagonizes mGluR5 receptor reduces neuropathic pain in mice","volume":"158","author":"Peterson","year":"2017","journal-title":"Pain"},{"key":"B218","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fpsyt.2017.00052","article-title":"In vitro and in vivo profile of PPL-101 and PPL-103: mixed opioid partial agonist analgesics with low abuse potential","volume":"8","author":"Khroyan","year":"2017","journal-title":"Front Psychiatry"},{"key":"B219","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1124\/mol.117.109561","article-title":"Pharmacologic evidence for a putative conserved allosteric site on opioid receptors","volume":"93","author":"Livingston","year":"2018","journal-title":"Mol Pharmacol"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fpsyt.2018.00119\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T21:28:37Z","timestamp":1751578117000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fpsyt.2018.00119\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,23]]},"references-count":219,"alternative-id":["10.3389\/fpsyt.2018.00119"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2018.00119","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,23]]},"article-number":"119"}}